• Skip to primary navigation
  • Skip to main content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

Probiodrug

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact

News · January 4, 2012

Probiodrug AG Raises Additional EUR15 Million to Advance Its Clinical Program

HALLE/SAALE, Germany, Jan. 4 2012 - Probiodrug AG today announced it has secured EUR15 million additional financing for the ongoing development of its glutaminyl cyclase (QC) inhibitor program. The …

News · September 8, 2011

ProBiodrug – Neurodegeneration bei Alzheimer-Erkrankung: Schlüsselrolle von QC

Probiodrug veröffentlicht neue Erkenntnisse zur Entstehung von Alzheimer im Journal of Neuroscience Halle/Saale, 8. September 2011 -- Die Probiodrug AG, ein biopharmazeutisches Unternehmen, das sich …

News · July 20, 2011

Probiodrug discovered fundamentally new active principle for the treatment of inflammatory diseases

Publikation in EMBO Molecular Medicine erläutert kausale Rolle des Enzyms iso-Glutaminylzyklase (isoQC) Halle/Saale, 20. Juli 2011, 08:00 Uhr MESZ -- Die Probiodrug AG, ein biopharmazeutisches …

News · March 8, 2011

Probiodrug and its collaborators will present novel insights into the pathophysiology of AD and biomarkers at AD/PD 2011 in Barcelona

Halle/Saale, March 08th 2011 -- Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a particular …

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact